Targeting the interleukin pathway in the treatment of asthma
Top Cited Papers
- 1 September 2015
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 386 (9998), 1086-1096
- https://doi.org/10.1016/s0140-6736(15)00157-9
Abstract
No abstract availableFunding Information
- Natural Environment Research Council
- National Institute for Health and Care Research
- National Institute of Environmental Health Sciences
- Medical Research Council
This publication has 80 references indexed in Scilit:
- Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsJournal of Allergy and Clinical Immunology, 2013
- A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthmaEuropean Respiratory Journal, 2012
- Lebrikizumab Treatment in Adults with AsthmaNew England Journal of Medicine, 2011
- A randomized, double‐blind, placebo‐controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthmaClinical and Experimental Allergy, 2011
- Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research ProgramAmerican Journal of Respiratory and Critical Care Medicine, 2010
- T-helper Type 2–driven Inflammation Defines Major Subphenotypes of AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Proteases Induce Production of Thymic Stromal Lymphopoietin by Airway Epithelial Cells through Protease-Activated Receptor-2The Journal of Immunology, 2009
- Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroidsProceedings of the National Academy of Sciences of the United States of America, 2007
- Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research ProgramJournal of Allergy and Clinical Immunology, 2007
- Cytokines in asthmaThorax, 1999